Press

GreenLight Biosciences in the News

GreenLight Supercharges Efforts with $102M in Funding

BOSTON, June 16, 2020 – GreenLight Biosciences today announced it has raised an oversubscribed $102 million round of funding from new and existing investors to rapidly expand production of its RNA products for agricultural and life sciences applications, including an expansion into new RNA-based therapies.

Read More

GreenLight Supercharges Efforts with $102M in Funding

BOSTON, June 16, 2020 – GreenLight Biosciences today announced it has raised an oversubscribed $102 million round of funding from new and existing investors to rapidly expand production of its RNA products for agricultural and life sciences applications, including an expansion into new RNA-based therapies.

$17M Raised for COVID-19 Vaccine Manufacturing

BOSTON, May 12, 2020 /PRNewswire/ — GreenLight Biosciences today announced it has closed an oversubscribed $17M special purpose funding round from new and existing investors to build out its scalable mRNA production capability targeting the production of billions of doses of COVID-19 vaccine.

GreenLight CEO Nominated for the Belisario Domínguez Medal of Honor

MEDFORD, Mass., Sept. 19, 2019 /PRNewswire/ — Andrey Zarur, Ph.D., co-founder, president and CEO of GreenLight Biosciences, Inc., has been nominated as a candidate for the Medalla de Honor “Belisario Domínguez” del Senado de la República (Belisario Domínguez Medal of Honor) by the Mexican Senate.

GreenLight Welcomes Susan Keefe as CFO

MEDFORD, Mass., June 11, 2019 /PRNewswire/ — GreenLight Biosciences, Inc., the bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications, welcomes Susan Keefe as chief financial officer to lead the company\’s financial strategy and facilitate its growth plan.

GreenLight Boosts R+D Capabilities with Key Hires

MEDFORD, Mass., May 31, 2019 /PRNewswire/ – GreenLight Biosciences, Inc., the bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications, announced several new hires to augment its plant science R&D team: David Culley, head of fungicide innovation; Brian Manley, head of field development; Laurent Mézin, head of regulatory; Ken Narva, head of entomology; Cris Oppert, crop protection scientist; and Krishna Sridharan, head of data science.

GreenLight Hires Commercial Team to Bring Targeted Biocontrol Products to Market

MEDFORD, Mass., March 4, 2019 /PRNewswire/ – GreenLight Biosciences, Inc., the bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications, announced the hiring of three experienced agricultural leaders as the company’s commercial team. Ron Flannagan has been named director, technical portfolio management; Joe Hanson joins as director, market development; and Catie Lee will serve as senior marketing manager.

GreenLight Announces $50 Million Funding Round

MEDFORD, Mass., Jan. 8, 2019 /PRNewswire/ — GreenLight Biosciences, Inc., the bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications, announced today a $50 Million first closing of its latest funding round. The round was led by S2G Ventures, Baird Capital and Blue I/O. Several additional top-tier investors, including Continental Grain Company, Tao Capital Partners and Alexandria Venture Investments, joined the investor syndicate. The majority of existing GreenLight investors also participated in the oversubscribed round.

GreenLight Welcomes New Chief Commercial Officer

MEDFORD, Mass., July 24, 2018 /PRNewswire/ — GreenLight Biosciences, Inc., a biotechnology company developing RNA-based products for agricultural and pharmaceutical applications, today announced that Mick Messman has joined the Company as Chief Commercial Officer. Mr. Messman has over 20 years of global agricultural sales, marketing, business development and operations experience. Prior to joining GreenLight, he spent the last 5 years building and leading the seed applied and biologicals crop protection business at Corteva Agriscience, a division of DowDuPont.

GreenLight Announces Series D Financing, Unveils RNA Strategy

MEDFORD, Mass., Sept. 13, 2017 /PRNewswire/ — GreenLight Biosciences, Inc. announced today the completion of its $18 million Series D round of financing led by Fall Line Capital. S2G Ventures, Lewis and Clark Ventures, and Macro Capital Investments participated in the round, along with the majority of GreenLight\’s existing investors, including Kodiak Venture Partners, MLSCF, Syngenta Ventures and others. GreenLight is harnessing its Cell-Free Bioprocessing® platform to develop a portfolio of RNA-based products for use in agriculture.

GreenLight to Present at the BIO World Congress on Industrial Biotechnology

BOSTON, July 18, 2017 /PRNewswire/ — GreenLight Biosciences, Inc., a biotechnology company producing novel RNA-based products for agricultural, healthcare and other applications, today announced that management will present at the BIO World Congress on Industrial Biotechnology at the Palais des Congres in Montreal, Canada. The presentation entitled “A novel platform for development of double-stranded RNA agricultural products” will be delivered by Dr. Andrey J. Zarur, Chairman and CEO of GreenLight, on Wednesday July 26th at 10:30 a.m. ET.

Join the GreenLight Revolution

Learn more about how GreenLight Biosciences is enabling innovative technologies to protect the health of people and the planet. We are always looking to meet new partners, new colleagues or anyone interested to learn more about RNA.

CONTACT US JOIN OUR TEAM